慢加急性肝衰竭的发病机制和治疗现状  

Current status of pathogenesis and treatment of acute-on-chronic liver failure

作　　者：蒙荫杰(综述) 邱华 毛德文(审校)[3] MENG Yinjie;QIU Hua;MAO Dewen(Graduate School of Guangxi University of Chinese Medicine,Nanning 530000,China;Department of traditional Chinese Medi-cine,Guangxi Medical University Affiliated Tumor Hospital,Nanning 530000,China;Department of Hepatology,the First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning 530000,China)

机构地区：[1]广西中医药大学研究生院,南宁530000 [2]广西医科大学附属肿瘤医院中医科,南宁530000 [3]广西中医药大学第一附属医院肝病科,南宁530000

出　　处：《西南医科大学学报》2023年第3期267-271,共5页Journal of Southwest Medical University

基　　金：国家科技重大专项课题(2018ZX10725506-002);国家中医临床研究基地建设项目(国中医药科技函[2018]131号);国家自然科学基金资助项目(81860889);第二批广西高层次骨干人才培养139计划(桂卫科教发[2018]22号);广西中医药大学一流学科建设开放课题(2019XK020)。

摘　　要：慢加急性肝衰竭(acute-on-chronic liver failure,ACLF)是一种在慢性肝病基础上出现急性黄疸加深和凝血功能障碍的综合征,可合并一个或多个肝外器官衰竭,治疗难度大,病死率达50%以上。ACLF的发病机制复杂,至今尚未阐明,这也是长期以来ACLF临床疗效未获得根本性突破的重要原因之一。本文将结合最新的循证医学证据对ACLF的病因、发病机制及治疗进行综述,以期有助于了解ACLF的发病机制及为临床治疗方案的选择提供参考。Acute-on-chronic liver failure(ACLF)is a syndrome of acute jaundice deepening and coagulopathy on the basis of chronic liver disease,which can be complicated by one or more extrahepatic organ failure.It is difficult to treat and the fatality rate is more than 50%.The complex pathogenesis of ACLF has not yet been clarified,which is one of the important reasons why the clinical ef⁃ficacy of ACLF has not achieved a fundamental breakthrough for a long time.This paper reviewed the etiology,pathogenesis and treat⁃ment of ACLF based on the latest evidence-based medical evidence,in order to help understand the pathogenesis of ACLF and provide reference for clinical workers to choose treatment plans.

关 键 词：慢加急性肝衰竭 急性肝衰竭 发病机制 

分 类 号：R57[医药卫生—消化系统]